Concordia Purchases Covis Drugs For $1.2 Billion

covis pharma

Concordia Healthcare has announced that it is purchasing Covis Pharma and Covis Injectables for a deal that totals $1.2 billion in cash. In the deal, Concordia acquires 18 branded drugs and authorized generic products from Concordia. The therapeutic areas include cardiovascular, the central nervous system, oncology, and acute care. “Covis’ strong commercial momentum will have an immediate and material impact on our top and bottom line financial results,” Concordia CEO Mark Thompson said in a statement. “In the longer-term, this transaction creates greater scale and diversification for Concordia, which should support the continued execution of our aggressive growth plans.”

Read the source article at

About the Author

Leave a Reply